FinscoFinsco

Beta Bionics (US.BBNX)

Capital Allocation Audit · Period: 2022 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.BBNX · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion106.3%→
ROE-17.7%↓
Cash Conversion-→
D/E Ratio0.03↓
Gross Margin59.3%↑
US.BBNX (Beta Bionics) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   106.3%    →
ROE              -17.7%    ↓
Cash Conversion       -    →
D/E Ratio          0.03    ↓
Gross Margin      59.3%    ↑
Key Metrics
US.BBNX (Beta Bionics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 106.3% →
ROE -17.7% ↓
Cash Conversion - →
D/E Ratio 0.03 ↓
Gross Margin 59.3% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies